- Home
- NINE vs ESLA Comparison
NINE vs ESLA Comparison
Compare NINE & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NINE
- ESLA
- Stock Information
- Founded
- NINE 2011
- ESLA 2021
- Country
- NINE United States
- ESLA United States
- Employees
- NINE N/A
- ESLA N/A
- Industry
- NINE Oilfield Services/Equipment
- ESLA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NINE Energy
- ESLA Health Care
- Exchange
- NINE Nasdaq
- ESLA Nasdaq
- Market Cap
- NINE 50.4M
- ESLA 41.6M
- IPO Year
- NINE 2018
- ESLA N/A
- Fundamental
- Price
- NINE $1.45
- ESLA $0.91
- Analyst Decision
- NINE
- ESLA
- Analyst Count
- NINE 0
- ESLA 0
- Target Price
- NINE N/A
- ESLA N/A
- AVG Volume (30 Days)
- NINE 1.4M
- ESLA 16.9K
- Earning Date
- NINE 10-31-2024
- ESLA 11-14-2024
- Dividend Yield
- NINE N/A
- ESLA N/A
- EPS Growth
- NINE N/A
- ESLA N/A
- EPS
- NINE N/A
- ESLA N/A
- Revenue
- NINE $556,751,000.00
- ESLA N/A
- Revenue This Year
- NINE N/A
- ESLA N/A
- Revenue Next Year
- NINE $3.95
- ESLA N/A
- P/E Ratio
- NINE N/A
- ESLA N/A
- Revenue Growth
- NINE N/A
- ESLA N/A
- 52 Week Low
- NINE $0.75
- ESLA $0.63
- 52 Week High
- NINE $3.26
- ESLA $3.23
- Technical
- Relative Strength Index (RSI)
- NINE 64.68
- ESLA 53.92
- Support Level
- NINE $1.10
- ESLA $0.74
- Resistance Level
- NINE $1.29
- ESLA $0.99
- Average True Range (ATR)
- NINE 0.18
- ESLA 0.09
- MACD
- NINE 0.02
- ESLA 0.02
- Stochastic Oscillator
- NINE 77.59
- ESLA 72.88
About NINE Nine Energy Service Inc.
Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer and autoimmune diseases.